… antivirals for COVID-19 treatment. Studies that were not randomized controlled trials or that
did not include treatment of COVID-19 with approved antivirals … antiviral efficacy for COVID-19 …

… In this study, we included only patients who completed oral antiviral treatments for their first
episodes of COVID-19, with at least three nasopharyngeal specimens sequentially collected …

… in high-risk COVID-19 patientsCitation 15 . The oral antiviral nirmatrelvir/ritonavir inhibits
the … the risk of progression to severe COVID-19 compared with placebo among symptomatic …

… antivirals are currently available for COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (… Oral LL-37 antiviral peptide (CAS001) was another promising candidate and …

… patients Lopinavir/Ritonavir 99 400 mg/100 mg twice daily Oral 14 Yes Lopinavir–ritonavir
administration is not superior to standard care in management of adult patients with severe …

… treatment of COVID-19. In addition, here we describe innovative drugs whose antiviral effect
… Analysis of laboratory and clinical data suggests that current antivirals successfully combat …

… of COVID-19 vaccines, effective oral antiviral drugs are urgently needed. Here, we describe
the discovery of S-217622, the first oral … S-217622 exhibited antiviral activity in vitro against …

… oral antiviral drug paxlovid significantly reduces hospital admissions and deaths among
people with covid-19 … three days of covid-19 symptoms starting, the risk of covid related hospital …

… confirmed COVID-19 and mild-to-moderate illness who received an oral antiviral prescription
… The aim was to assess safety and effectiveness of oral antivirals in individuals ≥80 years …

… coronavirus. One of the drugs which has recently garnered much attention, especially in India,
is an anti-viral … the present pandemic to elucidate its role in the management of COVID-19. …